Association of Platelet Binding to Lymphocytes with B Cell Abnormalities and Clinical Manifestations in Systemic Lupus Erythematosus

Table 1

Demographic, clinical, and laboratory characteristic data of study patients.

	SLE patients	HD
General conditions
Age; year,
Gender (%) () women	100 (21)	75 (12)
Years of evolution,
SLEDAI; mean (range)	2.62 (0-12)
Laboratory parameters
ESR^a (mm/h, )
CRP^b (mg/l, )
Complement C3 (mg/dl, )
Complement C4 (mg/dl, )
Decreased C3 or C4 (%) ()	80.95 (17)
Anti-dsDNA (U/ml), mean (range)	74.8 (22-300)
Positive anti-dsDNA (%) ()	42.8 (9)
Positive ANA (%) ()	95.23 (20)
Positive anti-Sm (%) ()	4.7 (1)
Positive antiphospholipid antibody (%) ()	14.28 (3)
Leukopenia and/or lymphopenia (%) ()	14.28 (3)
Clinical features
Renal involvement (%) ()	23.8 (5)
Hematuria	23.8 (5)
	23.8 (5)
Cutaneous involvement (%) ()	28.57 (6)
Oral or nasal ulcers	4.7 (1)
Alopecia	4.7 (1)
Photosensitivity	23.8 (5)
Butterfly erythema	9.5 (2)
Arthritis (%) ()	19.1 (4)
Nervous system disorder	4.7 (1)
Treatment (%) ()
None	9 (2)
Mycophenolate	14 (3)
Prednisone	48 (10)
Hydroxychloroquine	62 (13)
Azathioprine	24 (5)
Tacrolimus	9 (2)
NSAID^c	14.28 (3)
Aspirin	23.8 (5)

^aESR: erythrocyte sedimentation rate. ^bCRP: C-reactive protein. ^cNSAID: nonstereoidal anti-inflammatory drugs.